Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in Interest ReceivablesChange in Net LoansChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Asset Writedowns and Impairment (2020 - 2023)

iBio (IBIO) has disclosed Asset Writedowns and Impairment for 4 consecutive years, with $3.1 million as the latest value for Q4 2023.

  • On a quarterly basis, Asset Writedowns and Impairment changed N/A to $3.1 million in Q4 2023 year-over-year; TTM through Jun 2024 was $3.4 million, a 66.63% increase, with the full-year FY2024 number at $3.1 million, down 82.68% from a year prior.
  • Asset Writedowns and Impairment was $3.1 million for Q4 2023 at iBio, down from $17.3 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $17.3 million in Q2 2023 to a low of -$17.1 million in Q1 2023.
  • A 3-year average of $982800.0 and a median of $1.8 million in 2022 define the central range for Asset Writedowns and Impairment.
  • Biggest YoY gain for Asset Writedowns and Impairment was 884.94% in 2023; the steepest drop was 884.94% in 2023.
  • iBio's Asset Writedowns and Impairment stood at -$197000.0 in 2021, then skyrocketed by 993.4% to $1.8 million in 2022, then skyrocketed by 76.14% to $3.1 million in 2023.
  • Per Business Quant, the three most recent readings for IBIO's Asset Writedowns and Impairment are $3.1 million (Q4 2023), $17.3 million (Q2 2023), and -$17.1 million (Q1 2023).